Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The National Institute on Drug Abuse (NIDA) seeks to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval.  


  • Letter of Intent Due Dates: 30 days before the application due date
  • Application Due Date(s): Applications will be accepted on a rolling basis, beginning on September 3, 2022. 

PAR-22-202 Expiration Date September 02, 2025

Agency Website



Amount Description

Application budgets are limited to $5 million per year for direct costs and need to reflect the actual needs of the proposed project.

The maximum period of support is 3 years.

    Funding Type





    Medical - Basic Science
    Medical - Clinical Science
    Medical - Translational

    External Deadline

    September 1, 2025